The new drug Zolgensma of Novartis has lately been approved for marketing by the U.S. FDA to treat pediatric patients with spinal muscular atrophy (SMA). SMA is a rare disease (orphan disease), with the incidence of only 1-2/100,000. It's worth mentioning that as gene therapy, Zolgensma is priced at USD2.125 million/time which is sky-high. This causes people to think about the choice of rare disease drugs: for patients, it is a question as to whether to choose biologics (expensive) or small molecule drugs (cheap); for pharmaceutical practitioners, choosing which drugs for development is also a question for thought.
I. The "orphan drug" legislation behind the expensive prices
Fig. 1 Chronology of Orphan Disease Legislation and Orphan Drug Development
Development of drugs for rare diseases tends to be relatively slow owing to characteristics such as small patient base and relatively lagging mechanism research thereof; the relatively small market after drug development will often discourage and even kill the enthusiasm of pharmaceutical enterprises for the development of such drugs. As a result, the U.S. took the lead in promulgating the Orphan Drug Act (ODA, Fig. 1) in 1983 and thereafter many countries have legislated for rare diseases in succession. Those acts have undoubtedly promoted orphan drug development to some extent.
However, some ODAs at present have some undeniable drawbacks. Terms such as "independently pricing" and "market exclusivity" will lead to the market monopoly of some orphan drugs and "sky-high prices" unaffordable by most patients, and to some extent promote R&D institutions and enterprises to develop biologics that are generally priced higher and difficult to imitate. According to statistics, biologics have only flourished in recent years, however, rare disease drug approvals have accounted for 36% of the total in recent years, showing a rising trend. According to an insider, expensive drug prices will reduce patients’ access to corresponding drugs and seriously impact the sustainability of the public health system.
II. Biologics or small molecule drugs? Taking lysosomal storage diseases (LSDs) for an instance
Rare diseases are a major public health issue facing each country and are a huge challenge to the medical world.
Market shares of biologics have grown bigger and bigger in recent years owing to the rapid development of biomedicine, which restricts the room of small molecule drugs. Then, regarding biologics and small molecule drugs, which are better rare disease drugs? Whose overall treatment costs are lower? Those are questions for thought.
Fig. 2 Orphan Drug Development
Let us here talk about advantages and disadvantages and development patterns of biologics and small molecule drugs by taking LSDs for instance.
A. Development and advantages and disadvantages of biologics for LSDs
LSDs are monogenetic diseases where the mutation in a gene encoding for a lysosomal protein results in lysosomal failure and the subsequent accumulation of substrates, which ultimately leads to cell dysfunction and cell death. LSDs include Gaucher disease (GD, the LSD with the highest prevalence), Fabry disease, GM1 gangliosidosis (GM1), Pompe disease, α-mannosidosis (AM), Tay–Sachs disease (TSD), Niemann–Pick disease (NP), or the mucopolysaccharidosis (MPS). Most LSDs present as pediatric progressive neurodegenerative diseases.
As a biological therapy, enzyme replacement therapy (ERT) is available for a small proportion of the LSDs (Fig. 1, left side). The ERT developed by Brady and his colleagues for type 1 GD and approved by the FDA in 1991 remains the most successful example i...
(All Rights Reserved)